中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
25期
317-319
,共3页
赵美燕%王海燕%郑瑞莲%顿晓熠%陈尧
趙美燕%王海燕%鄭瑞蓮%頓曉熠%陳堯
조미연%왕해연%정서련%돈효습%진요
2型糖尿病%中药复方%胰岛素抵抗%胰岛β细胞功能
2型糖尿病%中藥複方%胰島素牴抗%胰島β細胞功能
2형당뇨병%중약복방%이도소저항%이도β세포공능
Type 2 diabetes%Traditional Chinese medicine%Insulin resistance%β-cell function
目的观察中药复方对2型糖尿病患者胰岛素抵抗和胰岛β细胞功能的影响。方法将483名患者按照诊断标准分为五组,其中2型糖尿病治疗组(T2DM-T组)103名,糖耐量受损治疗组(IGR-T组)95名,2型糖尿病对照组(T2DM-C组)91名,糖耐量受损对照组(IGR-C组)88名,糖耐量正常组(NGT组)106名,治疗组采用中药复方治疗,阳性对照组口服二甲双胍。分别用胰岛素作用指数(IAI)及稳态模型评估的胰岛素抵抗指数(HOMA-IR)评价胰岛素敏感性,用早期胰岛素分泌指数(ΔI30/ΔG30)、修正的胰岛β细胞功能指数(MBCI)、基础胰岛素分泌功能指数(HOMA-β)以及葡萄糖处置指数(DI)评估胰岛β细胞功能。结果各组治疗前与NGT组比较, T2DM组的IAI和HOMA-IR存在统计学差异;T2DM组和IGR组的ΔI30/ΔG30、MBCI、HOMA-β、DI四个指标均存在显著差异;各组治疗后与治疗前比较发现,T2DM组与IGR组的IAI显著升高,T2DM组的HOMA-IR显著降低,但是IGR组的HOMA-IR基本没有发生变化,差异无统计学意义;ΔI30/ΔG30、HOMA-β、DI三个指标均存在统计学差异,MBCI差异无统计学意义。结论中药复方具有降糖疗效,改善胰岛素敏感性,有效地缓解胰岛β细胞功能降低,调节糖脂代谢紊乱。
目的觀察中藥複方對2型糖尿病患者胰島素牴抗和胰島β細胞功能的影響。方法將483名患者按照診斷標準分為五組,其中2型糖尿病治療組(T2DM-T組)103名,糖耐量受損治療組(IGR-T組)95名,2型糖尿病對照組(T2DM-C組)91名,糖耐量受損對照組(IGR-C組)88名,糖耐量正常組(NGT組)106名,治療組採用中藥複方治療,暘性對照組口服二甲雙胍。分彆用胰島素作用指數(IAI)及穩態模型評估的胰島素牴抗指數(HOMA-IR)評價胰島素敏感性,用早期胰島素分泌指數(ΔI30/ΔG30)、脩正的胰島β細胞功能指數(MBCI)、基礎胰島素分泌功能指數(HOMA-β)以及葡萄糖處置指數(DI)評估胰島β細胞功能。結果各組治療前與NGT組比較, T2DM組的IAI和HOMA-IR存在統計學差異;T2DM組和IGR組的ΔI30/ΔG30、MBCI、HOMA-β、DI四箇指標均存在顯著差異;各組治療後與治療前比較髮現,T2DM組與IGR組的IAI顯著升高,T2DM組的HOMA-IR顯著降低,但是IGR組的HOMA-IR基本沒有髮生變化,差異無統計學意義;ΔI30/ΔG30、HOMA-β、DI三箇指標均存在統計學差異,MBCI差異無統計學意義。結論中藥複方具有降糖療效,改善胰島素敏感性,有效地緩解胰島β細胞功能降低,調節糖脂代謝紊亂。
목적관찰중약복방대2형당뇨병환자이도소저항화이도β세포공능적영향。방법장483명환자안조진단표준분위오조,기중2형당뇨병치료조(T2DM-T조)103명,당내량수손치료조(IGR-T조)95명,2형당뇨병대조조(T2DM-C조)91명,당내량수손대조조(IGR-C조)88명,당내량정상조(NGT조)106명,치료조채용중약복방치료,양성대조조구복이갑쌍고。분별용이도소작용지수(IAI)급은태모형평고적이도소저항지수(HOMA-IR)평개이도소민감성,용조기이도소분비지수(ΔI30/ΔG30)、수정적이도β세포공능지수(MBCI)、기출이도소분비공능지수(HOMA-β)이급포도당처치지수(DI)평고이도β세포공능。결과각조치료전여NGT조비교, T2DM조적IAI화HOMA-IR존재통계학차이;T2DM조화IGR조적ΔI30/ΔG30、MBCI、HOMA-β、DI사개지표균존재현저차이;각조치료후여치료전비교발현,T2DM조여IGR조적IAI현저승고,T2DM조적HOMA-IR현저강저,단시IGR조적HOMA-IR기본몰유발생변화,차이무통계학의의;ΔI30/ΔG30、HOMA-β、DI삼개지표균존재통계학차이,MBCI차이무통계학의의。결론중약복방구유강당료효,개선이도소민감성,유효지완해이도β세포공능강저,조절당지대사문란。
Objective To observe the effect of compound on insulin resistance in patients with type 2 diabetes and pancreaticβ-cell function. Methods 483 patients divided into ifve groups according to diagnostic criteria, including type 2 diabetes group (T2DM-T group) 103, impaired glucose tolerance treated group (IGR-T group) 95 type 2 diabetic control group (T2DM-C group) 91, impaired glucose tolerance group (IGR-C group) 88, normal glucose tolerance (NGT group) 106, the treatment group were treated with traditional Chinese medicine treatment, the positive control group was treated with metformin. Respectively, with insulin index (IAI) and homeostasis model assessment insulin resistance index (HOMA-IR) evaluation of insulin sensitivity, with the early insulin secretion index (ΔI30/ΔG30), modiifedβ-cell function index (MBCI), based insulin secretion index (HOMA-β) and glucose disposition index (DI) assessment ofβ-cell function. Results The pre-treatment group compared with NGT, T2DM group of IAI and HOMA-IR statistical difference;T2DM group and the IGR groupΔI30/ΔG30, MBCI, HOMA-β, DI four indicators are signiifcantly different;the group after treatment compared with before treatment found that, T2DM and IGR group of IAI group were signiifcantly higher, T2DM group was signiifcantly lower HOMA-IR, but the IGR group, HOMA-IR did not change the basic difference was not statistically signiifcant;ΔI30/ΔG30, HOMA-β, DI three indicators are there signiifcant differences, MBCI difference was not statistically signiifcant. Conclusion Chinese herbal compound has a hypoglycemic effect, improve insulin sensitivity, effective mitigation to reduceβ-cell function, regulating glucose and lipid metabolism disorders.